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A B S T R A C T
The human DEAD-box helicase DDX3 is a multi-functional protein involved in the regulation of gene expression
and additional non-conventional roles as signalling adaptor molecule that are independent of its enzymatic RNA
remodeling activity. It is a nucleo-cytoplasmic shuttling protein and it has previously been suggested that
dysregulation of its subcellular localization could contribute to tumourigenesis. Indeed, both tumour suppressor
and oncogenic functions have been attributed to DDX3. In this study, we investigated the regulation of DDX3’s
nucleocytoplasmic shuttling. We confirmed that an N-terminal conserved Nuclear Export Signal (NES) is re-
quired for export of human DDX3 from the nucleus, and identified three regions within DDX3 that can in-
dependently facilitate its nuclear import. We also aimed to identify conditions that alter DDX3’s subcellular
localisation. Viral infection, cytokine treatment and DNA damage only induced minor changes in DDX3’s sub-
cellular distribution as determined by High Content Analysis. However, DDX3’s nuclear localization increased in
early mitotic cells (during prophase) concomitant with an increase in DDX3 expression levels. Our results are
likely to have implications for the proposed use of (nuclear) DDX3 as a prognostic biomarker in cancer.
1. Introduction
DDX3 is a member of the DEAD-box family of RNA helicases which
has been implicated in a wide variety of processes that require RNA
remodeling, including splicing, mRNA export, transcriptional and
translational regulation, RNA decay and ribosome biogenesis
(Schröder, 2010). Eukaryotic cells spatially segregate transcription
(occurring in the nucleus) and mRNA translation (occurring in the cy-
toplasm), allowing for post-transcriptional regulation of gene expres-
sion. DDX3 has been implicated in both nuclear and cytoplasmic steps
of gene expression (e.g. regulation of transcription and translation),
albeit for distinct sets of genes. For example, DDX3 has been suggested
to regulate transcription of IFNβ, p21waf1/cip1 and E-Cadherin, with the
ability to either increase or decrease activation of their promoters
(Botlagunta et al., 2008; Chao et al., 2006; Soulat et al., 2008). On the
other hand, there is accumulating evidence for an important role for
DDX3 in the regulation of translation for specific mRNA transcripts (Lai
et al., 2010, 2008, 2015; Soto-Rifo et al., 2012, 2013). In addition, we
and others have identified non-conventional functions of DDX3 as a
signalling adaptor, e.g. in the signalling pathways downstream of anti-
viral pattern recognition receptors and in the death receptor signalling
pathway (Cruciat et al., 2013; Gu et al., 2013, 2017; Oshiumi et al.,
2010; Sun et al., 2008). Since DDX3 therefore has multiple distinct
nuclear functions (transcription, mRNA processing) and cytoplasmic
functions (translation and signalling), it is conceivable that a change in
its subcellular localisation could affect its participation in these pro-
cesses with consequences for cellular function. We were therefore in-
terested in investigating the regulation of its nuclear import and export.
It has already been demonstrated that DDX3 shuttles between the nu-
cleus and the cytoplasm; and both CRM-1 (the main protein exporter)
and TAP (the main mRNA exporter) have been implicated in its export
from the nucleus (Frohlich et al., 2016; Heerma van Voss et al., 2017b;
Lai et al., 2008; Schroder et al., 2008; Yedavalli et al., 2004). CRM-1
mediates export of proteins containing a conserved nuclear export
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sequence (NES) comprised of evenly spaced hydrophobic residues; with
leucine usually being most abundant (la Cour et al., 2004). Binding of
NES-containing proteins to CRM-1 is controlled by RanGTP, which
predominantly localises to the nucleus. While DDX3 contains a con-
served leucine-rich NES at its N-terminus, it is controversial whether
this NES is required for nuclear export of all DDX3 orthologues. In the
Xenopus DDX3 orthologue An3, the NES was clearly demonstrated to be
required for its nuclear export, as mutation of two crucial residues in
the NES, leucines 19 and 21, prevented export of An3 (Askjaer et al.,
1999, 2000). However, the same mutations to the NES did not prevent
export of hamster DDX3 (Sekiguchi et al., 2004). For human DDX3,
Yedavalli et al. showed binding to CRM-1 in an NES and Ran-GTP-in-
dependent manner. They suggested that human DDX3 instead interacts
with CRM1 through a region in its C-terminus and that it acts as a CRM-
1 co-factor in the rev-dependent export of HIV-1 RNAs, rather than
regular CRM-1 cargo (Yedavalli et al., 2004). In this paper, we clarify
that the N-terminal conserved NES in human DDX3 is functional and
required for its export from the nucleus.
In contrast to its export, the determinants of DDX3’s nuclear import
have not been investigated before. In this study, we therefore screened
for nuclear localization signals (NLSs) in the DDX3 sequence and de-
monstrate that DDX3 contains at least three distinct NLS sequences that
can independently mediate nuclear import of DDX3.
Finally, we also aimed to identify factors that alter the nuclear-cy-
toplasmic distribution of DDX3. Most studies have described a pre-
dominantly cytoplasmic localization of DDX3 in the steady state, with it
accumulating in the nucleus only when export is inhibited, indicating
that it constantly shuttles between the cytoplasm and the nucleus. It has
also been suggested that its predominant localization is altered during
malignant transformation of cells, and that mis-localisation of DDX3
could even contribute to malignancy. It was suggested that DDX3 is
mainly cytoplasmic in squamous cell carcinoma (SCC) cells, but nuclear
in normal epidermal cells (Chao et al., 2006). In contrast to this, a more
recent study demonstrated that high nuclear DDX3 expression (defined
as it being present in more than 1% of cells) correlated with worse
patient outcome, larger tumour size, positive lymph nodes and higher
grade cancers in cohorts of breast cancer and colon cancer patients
(Heerma van Voss et al., 2017b).
In light of this potential link between DDX3’s subcellular localiza-
tion (or its mis-localisation) and cancer cell malignancy, it is highly
relevant to identify the factors that influence the subcellular distribu-
tion of DDX3. Here, we demonstrate that DDX3’s expression and loca-
lization is regulated during cell cycle progression.
2. Materials and methods
2.1. Plasmids and antibodies
The mammalian expression constructs pCMV-HA-DDX3 and pCMV-
Myc-DDX3 have been described in our previous studies (Schroder et al.,
2008; Gu et al., 2013). pCMV-HA-DDX3 point mutations were in-
troduced following manufacturer’s instructions for the QuikChange
Site-Directed Mutagenesis Kit (Agilent), except for using Pfusion™ HiFi
polymerase (New England Biolabs). DDX3 truncation mutants (1–408,
409–662, 130–662, 139–662, 139–408, 22–662, 44–662) were gener-
ated by amplifying the relevant sequences by PCR from Ha-DDX3 and
inserting them into the pCMV-HA vector. NES-addition mutants, which
re-attached the NES region to N-terminal deletion mutants, were gen-
erated by amplifying the first 1–22 amino acids of DDX3 flanked by two
EcoR1 site. Constructs for truncation mutants were linearised using
EcoR1 and the NES 1–22 fragment was ligated into the EcoR1 site.
EYFP-tagged DDX3 constructs were generated by sub-cloning the re-
levant DDX3 sequences into a pCDNA3.1 vector containing the open
reading frame for EYFP. All generated constructs were sequence ver-
ified.
The antibodies used were anti-Myc mAb clone 9E10 (Sigma-
Aldrich), anti-HA mAb (Covance), anti-DDX3 (A300-474A, Bethyl
Laboratories), anti-CRM-1 (Novus Biologicals), anti-Ha AlexaFluor 594
(Invitrogen), anti-mouse AlexaFluor 488 (Invitrogen), anti-mouse
AlexaFluor 594 (Invitrogen), anti-rabbit AlexaFluor 488 (Invitrogen)
and anti-rabbit AlexaFluor 594 (Invitrogen), Cyclin A, B, and E (all
Santa Cruz).
2.2. Cell culture and transfection
HeLa and HEK293T cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with Glutamax™ (Gibco) supplemented with
10% fetal calf serum and 50 ng/ml gentamycin (Sigma-Aldrich).
Transient DNA transfections for immunofluorescent staining and im-
munoprecipitations/pull-downs were performed using the Calcium
Phosphate method. Transient transfection for high content analysis was
performed using GeneJuice ™(Merck/Novagen). Total amount of DNA
was kept constant by addition of empty vector.
2.3. CRM-1 Co-immunoprecipitation
Co-immunoprecipitations were performed on cell lysates of tran-
siently transfected HEK293T cells, which were harvested 24 h after
transfection. Cells were lysed in IP lysis buffer (50mM Hepes pH7.4,
150mM NaCl, 2 mM EDTA, 1% NP-40, 10% Glycerol, 10mM NaF, 1%
Triton X-100, 10mM DTT, protease inhibitors). 10% of the lysate was
retained as input control, 90% was used for the immunoprecipitation.
Cell lysates were incubated with 20 μl of Protein A/G agarose (Santa
Cruz) pre-coupled with anti-CRM-1 (Novus Biologicals) in the presence
(or absence) of recombinant His-RanQ69L protein (provided by Dr
Virginie Gautier, UCD) and 20mM GTP 4 °C overnight. The im-
munoprecipitated protein complexes were washed thoroughly and then
eluted by boiling in Laemmli sample buffer, before being subjected to
SDS–PAGE and Western-Blot analysis.
2.4. Immunofluorescent staining and confocal microscopy
Hela cells were seeded on sterile glass cover slips in 6-well plates
(and transfected with expression constructs where necessary). After
24 h, they were washed, fixed with 4% paraformaldehyde, and per-
meabilised with 0.5% Triton-X-100. After blocking with BSA, cells were
stained with the appropriate antibodies. Overexpressed DDX3 and
DDX3 mutants were mostly HA-epitope tagged (only the K230E mutant
is myc-epitope-tagged) and detected with antibodies against the epitope
tag. For detection of the HA-tagged proteins, we either used a directly
labelled anti-Ha antibody (anti-Ha-594, Invitrogen) or the same un-
labelled anti-Ha primary antibody clone (16B12) (Covance) followed by
Alexa-Fluor488- or AlexaFluor594-labelled anti-mouse secondary anti-
body (Invitrogen). Appropriate controls were included in the experi-
mental set-up in order to rule out non-specific binding of antibodies and
bleed-through of channels (e.g. secondary antibodies only, individual
stainings as well as co-stainings). After staining, cells were mounted in
SlowFade Gold Antifade Reagent containing DAPI (Invitrogen) on mi-
croscope slides and sealed using clear nail varnish. Cells were viewed
using an Olympus Fluoview Confocal Microscope; and analysed using
Olympus Fluoview FV10-ASW software. Multiple cells in several dif-
ferent frames were examined and recorded in each experiment, and
experiments were repeated at least twice, most were repeated three or
more times.
2.5. High content analysis
HeLa cells were grown in a 96wp and fixed and stained in the plate
as described above. After secondary antibody incubation, DAPI (Sigma-
Aldrich) was used at a concentration of 0.5 μg/ml to stain the nuclear
DNA and Phalloidin–Tetramethylrhodamine B isothiocyanate (Sigma-
Aldrich) was used at a concentration of 0.1μM to stain actin filaments.
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This was followed by further washing in PBS-Tween. Cells were then
covered with 200 μl PBS and analysed on a GE IN Cell Analyser 1000
(based in the Irish National Center for High Content Screening and
Analysis, Trinity College Dublin). Data was collated by IN cell Software
(GE Healthcare). DAPI and Phalloidin-staining were used to define
nuclear and cytoplasmic regions, respectively, which were used as a
mask for detection of changes in DDX3 staining. Each condition was
measured in duplicate wells, with 10 frames captured per well, and
between 1577 and 2401 cells analysed in total for each condition. The
fraction of DDX3 in the nucleus was calculated by dividing background-
corrected nuclear intensity (IxA) by (background-corrected cytoplasmic
intensity+ background-corrected nuclear intensity).
2.6. Cell cycle blocks
HeLa cells were arrested at different cell cycle stages by treatment
with different cell cycle inhibitors. A double thymidine block was used
to arrest cells in early S-Phase: HeLa cells were plated at 25–30%
confluency and grown in complete DMEM supplemented with 2mM
thymidine for 18 h. After this initial thymidine block, cells were washed
in PBS twice and released into fresh complete DMEM for 9 h. Cells were
then added to complete DMEM supplemented with 2mM thymidine for
17 h for the second block. To arrest cells at G2/M boundary, a thymi-
dine/nocodazole block was used: HeLa cells were plated at 40% con-
fluency and grown in complete DMEM supplemented with 2mM thy-
midine for 24 h. After initial thymidine block, cells were released into
fresh complete DMEM for 3 h. After release, 100 ng/ml nocodazole was
added to cells for 12 h. To arrest cells at the G0/G1 boundary, HeLa
cells at 3–40% confluency were washed twice in PBS and grown in
serum-free medium for 72 h. Where required, cells were released from
the different blocks into complete DMEM and harvested at specific time
points to monitor cell cycle progression by Western Blot analysis.
3. Results
3.1. DDX3’s nuclear export is mediated by CRM1 and dependent on its N-
terminal conserved NES
We first confirmed that DDX3’s export is largely dependent on CRM-
1, as previously observed by us and others. In HeLa cells, both en-
dogenous and overexpressed DDX3 were predominantly cytoplasmic,
but clearly accumulated in the nucleus after treatment with the specific
CRM-1 inhibitor Leptomycin B (LMB) (Fig. 1A and B). The fact that
DDX3 export is sensitive to LMB indicates that its export should be
mediated by a classical NES, because LMB inhibits CRM-1 function by
covalent modification of its NES-binding site (Kudo et al., 1998). As
mentioned, there is controversial data about the functionality of the
highly conserved N-terminal NES in different DDX3 orthologues. Thus,
we wanted to clarify whether the N-terminal NES is required for export
of human DDX3. We first demonstrated that a C-terminal deletion
mutant of DDX3, containing only the first recA-like domain, specifically
amino acids 1–408, also accumulates in the nucleus following LMB
treatment, confirming that its export still depends on CRM-1 despite
partial removal of the proposed C-terminal CRM-1 binding site in DDX3
(Yedavalli et al., 2004) (Fig. 1C). Next, we generated a DDX3 mutant
that does not contain the conserved N-terminal NES by truncating the
first 22 amino acids of DDX3. This Δ22 mutant clearly accumulated in
the nucleus in the absence of LMB treatment, suggesting it is not being
exported efficiently (Fig. 1D). We also imaged localisation of additional
N-terminal truncation mutants, including 44–662 (Δ44) (Supplemen-
tary Fig. 1a), 130–662 (Δ130) and 139–662 (Δ139). All of these also
accumulated in the nucleus as expected, and there was no additional
effect compared to the Δ22 mutant (Fig. 1D). Interestingly though, the
Δ139–662 mutant showed a more speckled distribution in the nucleus
compared to both the Δ130 and Δ22 mutant.
Next, we mutated two of the conserved leucine residues in the NES,
L19 and L21, to alanines. This was sufficient to disrupt DDX3 export, as
this NES mutant (mtNES) also clearly accumulated in the nucleus
without LMB treatment (Fig. 1E). Finally, we affixed the 1–22 region of
DDX3 containing the conserved NES back onto the Δ130 truncation
mutant of DDX3, which prior to this manipulation accumulated in the
nucleus like other N-terminal truncation mutants (see Fig. 1D). Addi-
tion of the NES largely restored localization of the Δ130 truncation
mutant to the cytoplasm and also conferred sensitivity to LMB treat-
ment (Fig. 1F). Similar effects were also seen when we affixed the NES
to the Δ44 and Δ139 truncation mutants (Supplementary Fig. 1a). In
addition, the NES (1–22 region of DDX3) was able to enhance export of
an unrelated protein (the transcription factor ZNF512) when we fused it
to its N-terminus (Supplementary Fig. 1b). These results clearly confirm
that the conserved leucine-rich region between aa 1 and 22 in DDX3
contains a functional NES.
Finally, we tested whether enzymatic activity of DDX3 is required
for nuclear export, because an ATPase-deficient mutant of its ortho-
logue An3 mutant was shown to accumulate in the nucleus (Askjaer
et al., 2000). However, the K230E mutant of human DDX3, which has
no ATPase or RNA unwinding activity, behaved like wild-type DDX3 in
our shuttling assays. It was largely cytoplasmic when expressed in cells,
and accumulated in the nucleus only after treatment with LMB
(Fig. 1G), thus suggesting that enzymatic activity is not required for
nuclear export of human DDX3.
Taken together, these experiments clearly demonstrate that the
conserved N-terminal NES and CRM-1 are required for efficient export
of human DDX3 from the nucleus, whereas its enzymatic activity is not.
3.2. DDX3 binding to CRM-1 is mediated by the N-terminal NES
To test whether the physical interaction between DDX3 and CRM-1
also depends on the N-terminal NES, we tried to co-immunoprecipitate
DDX3 or DDX3 mutants lacking either the N-terminal NES and/or the C-
terminal region with endogenous CRM-1. To this end, we transfected
cells with expression plasmids for HA-tagged wild-type DDX3, full-
length DDX3 containing the two leucine substitutions in the NES
(mtNES), a C-terminally truncated mutant (1–408), or an N- and C-
terminal deletion mutant (139–408). We then immunoprecipitated
endogenous CRM-1 from the cell lysates in the presence of recombinant
non-hydrolysable His-RanQ69L-GTP, which stabilizes CRM-1-cargo in-
teractions (Guttler et al., 2010). Under these conditions, wild-type
DDX3 and 1–408 DDX3 co-immunoprecipitated with CRM-1, while the
two DDX3 mutants lacking a functional N-terminal NES did not
(mtNES, 139–408) (Fig. 2). This suggests that DDX3 behaves like a
classical CRM-1 cargo protein, with both binding to CRM-1 and export
from the nucleus being dependent on the conserved leucine-rich NES
sequence in the N-terminus.
3.3. DDX3 contains at least two independent Nuclear Localization Signals
(NLS) in the N-terminal region
The cellular localization of DDX3 is influenced by the balance of
import and export, thus it is also important to understand how DDX3 is
imported into the nucleus. However, no information is available to date
about the determinants of DDX3’s nuclear import. From our experi-
ments studying DDX3’s nuclear export described above, we are also
able to draw some conclusions regarding DDX3’s import into the nu-
cleus, seeing as mutants that accumulate in the nucleus when export is
inhibited have to be imported in the first place. DDX3’s import there-
fore also does not require its enzymatic activity (Fig. 1G), and deletion
of the N-terminus or C-terminus do not prevent import (mutants
139–662 and 1–408 were imported into the nucleus) (Fig. 1D and C).
Nuclear localization signals (NLSs) are harder to identify than export
signals, as there are different importin proteins and their recognition
sequences are more variable. We used several NLS prediction software
programmes to identify putative NLSs in DDX3. The software PSORT II
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can identify classical NLS sequences in proteins (Nakai and Horton,
1999), and suggested a putative classical NLS between amino acids 211
and 219 of DDX3, thus located within the first recA-like domain. Using
site directed mutagenesis we changed two crucial positively charged
residues to alanines, namely the lysines at positions 215 and 217
(Fig. 3A). This ‘NLS1’ mutation was generated in the context of full
length DDX3 (NLS1- 1–662) and in the C-terminal truncation 1–408
(NLS1-1–408). We then transfected HeLa cells with expression
Fig. 1. Nuclear export of human DDX3 is mediated by CRM-1 and dependent on conserved N-terminal NES. For A and C–G, HeLa cells were transfected with
expression constructs for wild-type DDX3 (A), a C-terminally truncated DDX3 mutant, 1–408 (C), N-terminally truncated DDX3 mutants (D), the DDX3 mutant
carrying two mutations in the conserved NES (L19A/L21A), mtNES (E), a DDX3 mutant where the NES (1–22) was re-attached to the 130–662 truncation (F) and the
K230E mutant of DDX3 that is enzymatically inactive. The K230E mutant is myc-tagged and was stained with an anti-myc primary antibody. All other mutants and
WT-DDX3 are Ha-tagged and were stained with an anti-Ha primary antibody. Endogenous DDX3 (B) was stained with a primary antibody against the N-terminus of
DDX3. In all cases, a secondary antibody labelled with Alexa Fluor-488 was used. DAPI DNA stain was used to visualize the nucleus. Where indicated, cells were
treated with 20 nM Leptomycin B (LMB) for 3 h. Images shown are representative of 3–5 repeat experiments with multiple frames collected in each experiment.
Fig. 1H shows a schematic drawing of all DDX3 constructs used for this Figure and Supplementary Fig. 1a and summarises their localization and response to
Leptomycin B (LMB, +indicates that mutant accumulates in nucleus following LMB treatment).
Fig. 2. An intact N-terminal NES is required
for DDX3 binding to CRM-1. HEK293T cells
were transiently transfected with expression
constructs for Ha-tagged wild-type (WT)
DDX3, for full-length DDX3 carrying the two
point mutations in the NES (mtNES), for the
1–408 or the 139–408 truncation mutants.
Endogenous CRM-1 was then im-
munoprecipitated from cell lysates in the pre-
sence of recombinant non-hydrolysable His-
RanQ69L-GTP, which stabilizes CRM-1 cargo
interactions. Samples were then subjected to
SDS-PAGE and Western Blot analysis with an-
tibodies against the Ha epitope tag (detecting
DDX3) and CRM-1. Shown is one re-
presentative experiment out of two.
R. Brennan et al. European Journal of Cell Biology 97 (2018) 501–511
504
constructs for these NLS1 mutants, and treated the transfected cells
with LMB to inhibit nuclear export. Both the long and short NLS1
mutant were cytoplasmic in untreated cells as expected (not shown)
and nuclear in LMB-treated cells (Fig. 3B), indicating that import was
not affected by the mutations. This either suggests that the identified
putative NLS at position 211–219 is not functional, or that even the N-
terminal 1–408 fragment of DDX3 contains more than one redundant
NLS. We next used the software NucImport to identify further putative
NLSs, as it was suggested to identify NLSs better than previously pub-
lished software and is not restricted to classical NLSs (Mehdi et al.,
2011). NucImport identified a putative NLS at amino acids 259–264,
located in an exposed loop in the protein structure of DDX3 (Fig. 3C).
Mutagenesis of this putative NLS was carried out in the 1–408 truncated
DDX3, with a total of four amino acids (R259, Y260, R262, R263)
Fig. 3. DDX3 contains at least three redundant nuclear localization signals (NLSs). Openly available software programmes were used to identify putative
nuclear localization signals in the DDX3 protein sequence. Putative NLSs identified by PSORT II (Nakai and Horton, 1999) (A) and NucImport (Mehdi et al., 2011) (C)
are shown and were designated NLS1 and NLS2 respectively. Conserved amino acids forming the putative NLS are shown in red letters, and the amino acids changed
in our mutagenesis in green letters. The localization of the NLS2 motif in an exposed loop in the DDX3 structure (PDB 2l4l, (Hogbom et al., 2007)) is also shown in
(C), in an image generated by Pymol, with the amino acids we mutated in NLS2 highlighted in red. For B, D and E, expression vectors for DDX3 mutants were
transfected into HeLa cells, in B and D, the mutants were Ha epitope tagged and their localization was detected using a primary antibody against the Ha-tag. In E, we
compared the localization of a Ha-tagged 409–662 mutant and EYFP-tagged 409–662 and 409–572 mutants. DAPI DNA stain was used to visualize the nucleus.
Where indicated, cells were treated with 20 nM Leptomycin B (LMB) for 3 h to inhibit nuclear export. Images shown are representative of 2–4 repeat experiments
with multiple frames collected in each experiment. Fig. 3F shows a schematic drawing of all DDX3 constructs used for this Figure and Supplementary Fig. 3 and
summarises their localization in the absence and presence of Leptomycin B (LMB). (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article).
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changed to alanines, and the resulting mutant was called ‘NLS2’
(Fig. 3C). HeLa cells overexpressing HA-tagged NLS2 (1–408) were
treated with LMB to inhibit export. The NLS2 mutant was also cyto-
plasmic in untreated cells (not shown) and nuclear in cells treated with
LMB (Fig. 3D), suggesting that import was again not disrupted by
mutation of this second putative NLS. However, we next decided to
truncate the N-terminus in the NLS2 mutant and generated the
‘139–408 NLS2’ mutant. The wild-type 139–408 truncation of DDX3
localises to the nucleus in the absence of LMB treatment due to loss of
the NES, and shows a speckled distribution in the nucleus (Fig. 3D,
bottom row), similar to the 139–662 mutant (Fig. 1D). Interestingly, the
139–408 truncation carrying the NLS2 point mutations (Fig. 3D, middle
row) was markedly more cytoplasmic than either the 1–408 NLS2
mutant (in the presence of LMB, top row) or the wild-type 138–408
truncation (bottom row). This comparison suggested that there is an
additional NLS present in the N-terminal region (aa 1–139) that is able
to mediate import of the 1–408 construct in the absence of NLS2. NLS2
on the other hand is functional in the absence of the N-terminal NLS, as
it mediates import of the 139–408 truncation. We also further con-
firmed that the putative NLS1 investigated in Fig. 3A and B does not
contribute to import of the 139–408 truncation, by generating the
corresponding NLS1 139–408 mutant and the NLS1+2 139–408 double
mutant. The NLS1 139–408 mutant accumulated in the nucleus similar
to wild-type 139–408, and there was also no significant difference be-
tween NLS2 139–408 and the NLS1+1 139–408 double mutant (Sup-
plementary Fig. 3).
In conclusion, we have identified two functional NLSs in DDX3, one
in the N-terminal extension and one in the first recA-like domain, while
the only putative NLS identified by PSORT II appears to be non-func-
tional.
3.4. The C-terminal RecA-like domain of DDX3 is also independently
imported into the nucleus
We also observed nuclear localization of a truncation mutant com-
prising only the C-terminal part of DDX3, aa 409–662, which includes
the second recA-like domain and the flexible C-terminal extension, but
contains neither of the NLSs identified above (Fig. 3E). However, be-
cause the distribution of the 409–662 truncation mutant was quite
diffuse across both cytoplasm and nucleus, and because it is only ap-
proximately 30 kDa large, we considered that it might simply diffuse
into the nucleus passively. We thus increased the size of the truncation
mutant by sub-cloning it into a vector generating a fusion protein with
Enhanced Yellow Fluorescent Protein (EYFP). EYFP is approximately
27 kDa, therefore the resulting fusion protein is around 57 kDa and too
large to passively diffuse through the nuclear pore. We found that
409–662-EYFP and 409–572-EYFP mutants also localised to the nu-
cleus, maybe even more clearly than the Ha-tagged 409–662 protein
(Fig. 3E), suggesting that nuclear import is indeed facilitated in-
dependently for the C-terminal domain of DDX3. The 409–572 trun-
cation corresponds roughly to the second recA-like domain. None of the
NLS prediction software programmes identified a putative NLS in this
region, hence we were unable to further narrow down the sequence
responsible for mediating its import.
In summary, we demonstrated that DDX3 contains at least three
independent NLSs: one in the flexible N-terminus (N-NLS) (aa 1–139),
one between aa 259–263 in an exposed surface loop extending from the
first RecA like domain (NLS2), and one in the C-terminal RecA-like
domain between aa 409–572.
3.5. Can the subcellular localization of DDX3 be altered?
We were also interested in the question whether DDX3’s distribution
between the cytoplasm and the nucleus can be altered by cellular
conditions. In order to more objectively and quantitatively analyse the
subcellular distribution of DDX3, we used a High Content Analyser to
determine the nuclear/cytoplasmic ratio. To this end, we stained DDX3
in HeLa cells as usual, but combined it with a Phalloidin F-actin stain
(to define the cytoplasmic area) and the DAPI DNA stain (to define the
nucleus). The intensity of nuclear and cytoplasmic DDX3 staining was
determined for all cells in ten different fields per well (and two wells/
condition). This resulted in approximately 2000 cells being analysed for
each condition. For endogenous DDX3 in untreated HeLa cells, the
median value for the nuclear fraction ((IxA nucleus)/(IxA nucleus)
+(IxA cytoplasm)) was 0.185. As a control for our set-up, we treated
cells with LMB to inhibit nuclear export of DDX3. This clearly increased
the median value for the nuclear fraction to 0.329 (unpaired Student’s
T-test, p= 0) (Fig. 4A). We also calculated the percentages of cells that
fell into the 0–0.25, the 0.25–0.5 and the 0.5–1 range (with 1 re-
presenting fully nuclear DDX3). For untreated HeLa cells, 82.36% of
cells were in the lowest range of 0–0.25, 16.91% of cells in the 0.25–0.5
range, and 0.66% of cells in the highest range of 0.5–1. In contrast, for
LMB-treated HeLa cells, only 10.06% of cells were in the lowest range,
whereas 86.93% were in the 0.25–0.5 range and 3% in the 0.5–1 range
Fig. 4. Viral infection, cytokine treatment and DNA damage only induce minor alterations to DDX3’s nucleo-cytoplasmic distribution. HeLa cells were
treated with the indicated stimuli, and then fixed and stained for DDX3. In addition, the cells were stained with Phalloidin and DAPI to define the cytoplasm and
nucleus respectively. A: The graph depicts median values for the nuclear fraction of endogenous DDX3 as determined by High content analysis (HCA). B: HCA data
was re-analysed in order to identify sub-populations of cells with low (0–0.25), medium (0.25–0.5) and high (0.5–1) nuclear fractions of DDX3. Statistical analysis
was performed on (A) using an unpaired Student’s t-test. * p < 0.05, ****P < 0.0001, all compared to untreated cells. LMB=Leptomycin treatment B;
SeV=Sendai Virus infection for different time periods (in h=hours), TNF/IL1= TNFα/IL-1β treatment for 8 h, IFN= type I Interferon treatment (IFNα) for 24 h,
Eto= Etoposide treatment at 25 or 50 μM.
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(Fig. 4B). Thus, as expected, a clear shift towards increased localization
of DDX3 was observed with LMB treatment. We then used this system to
test the effects of a viral infection (Sendai Virus, SeV), cytokine sti-
mulation (TNFα/IL1β or type I interferon, IFN)) and DNA damage
(induced by etoposide treatment) on the nucleo-cytoplasmic distribu-
tion of DDX3. The median values for the nuclear fraction of DDX3 ap-
peared to remain largely unchanged for these treatments (Fig. 4A).
However, some of the small changes were statistically significant, in-
cluding small increases in DDX3’s nuclear fraction for SeV infection at
1 h (0.198, p= 1.8E-09) and 24 h (0.2, p= 0.02) and IFN treatment
(0.21, p= 1.67E-8). For these conditions, there was also a corre-
sponding small increase in the percentage of cells in the 0.25–0.5 range
(e.g. 19.75% for 1 h SeV infected cells compared to 16.91% in the un-
infected cells) and the 0.5–1 range (1.4% compared to 0.66%) (Fig. 4B).
For TNF/IL-1 stimulation, there was a statistically significant small
decrease in the median value for the nuclear fraction of DDX3 (0.172,
p=1.16E-21). Etoposide treatment decreased the median value for the
nuclear fraction very slightly to 0.182 (25 uM, p=5.75E-05)) and
0.186 (50 uM, p= 1.22E-08), but conversely there appeared to be a
slight increase in the percentage of cells in the highest 0.5–1 range
(0.83% for 50 μM Etoposide compared to 0.66% in untreated cells).
Despite the statistical significance of the data, it is questionable whe-
ther such small shifts in DDX3’s nucleo-cytoplasmic distribution result
in meaningful changes to cellular behaviour.
3.6. DDX3’s subcellular localization is affected by cell cycle stage
Finally, we decided to investigate whether the cell cycle stage af-
fects DDX3’s subcellular localization. To this end, we identified cells at
different stages of the cell cycle on our stained slides. They were
identified based on the shape of the cell and chromatin condensation
level, and by co-staining with α-Tubulin for visualization of the mitotic
spindle or phospho-Histone H3 antibody, which detects endogenous
levels of histone H3 only when phosphorylated at Ser28. This phos-
phorylation is tightly correlated with chromosome condensation during
mitosis and meiosis, and can therefore be used as a marker for mitotic
cells.
We first stained untreated ‘unsynchronised’ HeLa cells and identi-
fied mitotic cells based on the criteria outlined above. For example,
prophase/prometaphase cells were identified based on phospho-H3
staining and an intact rounded nucleus. Levels of nuclear DDX3 ap-
peared to be increased slightly in these cells (Fig. 5A, white arrows). We
also observed increased DDX3 staining around the aligned condensed
chromosomes during metaphase and anaphase (Fig. 5A, white arrow-
heads). We quantified nuclear localisation of DDX3 by determining the
Pearson’s Correlation Coefficient (PCC) between Alexa-Fluor488
staining (DDX3) and the DAPI nuclear stain for non-mitotic cells (i.e.
those not staining for phospho-H3) and mitotic cells (pro/prometaphase
and metaphase cells based on shape of nucleus). While the PCC was
negative for non-mitotic cells, it was 0.42 and significantly increased
for pro/prometaphase cells (p= 1.25E-5, unpaired t-test). Similar ob-
servations were made when DDX3 was co-stained with α-tubulin to
visualize the mitotic spindle (Fig. 5B). Again, DDX3 appeared to be
more nuclear during pro/prometaphase (white arrows), and to co-lo-
calise to some extent with the mitotic spindle (tubulin) during meta-
phase through to telophase/cytokinesis (white arrowheads) (Fig. 5B).
To further confirm these observations, we treated HeLa cells with cell
cycle inhibitors to arrest them at different mitotic stages. Cells were
arrested at the G0/G1 boundary with serum starvation, in early S-Phase
with a double thymidine block, or at the G2/M boundary with noco-
dazole, followed by staining and imaging of endogenous DDX3. HeLa
cells blocked at the G0/G1 or in S-Phase had cytoplasmic DDX3 (Fig. 5C
and D). HeLa cells blocked at the G2/M boundary with nocodazole
however had increased nuclear DDX3 (Fig. 5E). Nocodazole causes cells
to arrest in prometaphase, suggesting that DDX3 becomes more nuclear
during prophase. This is also consistent with our imaging of unarrested
HeLa cells, where DDX3 appeared to be more nuclear in cells identified
to be in prophase/prometaphase by Histone H3 staining and the mor-
phology of the nucleus and the cell (Fig. 5A).
3.7. Phosphorylation of DDX3 at threonine 204 and 323 does not regulate
its nuclear accumulation
DDX3 has been shown to be phosphorylated by Cyclin B at threo-
nines 204 and 323 during mitosis (Sekiguchi et al., 2007). Cyclin B
levels rise during early mitosis, and we thus hypothesized that phos-
phorylation of DDX3 by Cyclin B could mediate its observed nuclear
accumulation during prophase. To investigate this, we first tested an
antibody that is supposedly specific for DDX3 phosphorylated at
Thr323 available from Abcam (ab61043). In immunofluorescent
staining, this antibody produced a nuclear staining (which co-localised
with staining for a nuclear speckle marker) (data not shown), seemingly
supporting our hypothesis that DDX3 phosphorylation might lead to its
nuclear accumulation. However, when we tested the antibody in Wes-
tern Blots, it failed to produce a band at the correct size for DDX3
(73 kDa) and instead produced a band at 130 kDa (data not shown). We
thus suspect that this antibody cross-reacts with a 130 kDa protein
present in nuclear speckles, and is not suitable for specifically detecting
phosphorylated DDX3. We then generated mutants of DDX3 where we
substituted the threonines at positions 204 and 323 with either
phospho-deficient alanines (TA2 mutant) or phospho-mimetic aspartic
acid (TD2 mutant). HeLa cells were transfected with expression con-
structs of these DDX3 mutants and stained as previously described (for
the Ha-epitope tag). The phospho-deficient TA2 (T204A,T323A) and
the phosphomimetic TD2 (T204D,T323D) double mutants localised
predominantly to the cytoplasm (Fig. 6), suggesting that phosphoryla-
tion at these threonine residues is not driving nuclear accumulation of
DDX3. Import of DDX3 was also not affected by these mutations, as they
accumulated in the nucleus following treatment with LMB (Fig. 6).
In conclusion, while we provide evidence that DDX3 becomes more
nuclear during early mitosis (prophase and prometaphase) and might
stay associated with the mitotic spindle during chromosome segrega-
tion, we have been unable to identify the mechanism behind this
change in localization, having ruled out phosphorylation at threonines
204 and 323 as the cause.
3.8. DDX3 expression is upregulated during mitosis
We also wanted to determine whether protein levels of DDX3 are
altered during the cell cycle. First, we again used serum starvation,
double thymidine or nocodazole treatment to arrest Hela cells in G0/
G1, early S-Phase, or G2/M respectively, followed by western blot de-
tection of endogenous DDX3. Compared to untreated cells, HeLa cells
blocked at G0/G1 and in S-Phase had reduced levels of DDX3, while
cells blocked at G2/M with nocodazole had clearly increased levels of
DDX3 (Fig. 7A). We next decided to monitor changes in DDX3 ex-
pression more closely during cell cycle progression. To this end, HeLa
cells were blocked in early S-Phase using a double thymidine block, and
then released into growth medium. We took samples for western blot
analysis for 18 h after the release, and probed also for Cyclin E1 (highly
expressed during G1), Cyclin A (highly expressed during S and G2) and
Cyclin B (highly expressed during early M phase). Cyclin A was de-
tected from 0 h to 15 h after release with the strongest expression,
which should occur in G2 phase, being detected 6 h after release. Cyclin
B expression is expected to peak in early mitosis (M-phase) and then to
strongly decrease. We observed strong Cyclin B expression 6 and 9 h
after release, and its degradation had occurred by 12 h after release.
DDX3 levels were clearly increased 6 h and 9 h after release, before
decreasing again 12 h after release. The increased DDX3 levels therefore
correlated with the strongest expression of mitotic cyclin B, confirming
that DDX3 levels are increased in G2 and early M-phase. This is in
agreement with the observation made in Fig. 7A, where cells arrested at
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G2/M showed increased DDX3 expression.
In summary, we have demonstrated that DDX3’s expression and
subcellular localisation are regulated during the cell cycle. DDX3 pro-
tein expression increased in early M-phase (prophase/prometaphase),
also correlating with the cell cycle stage where its localization became
more nuclear. This further supports an important role for DDX3 during
mitosis, such as its proposed role during chromosome segregation
(Chen et al., 2017; Pek and Kai, 2011).
4. Discussion
Our study identified NLS and NES sequences in human DDX3 and
investigated the regulation of its nucleo-cytoplasmic shuttling, with the
aim of identifying factors that could lead to an alteration in its sub-
cellular distribution.
4.1. Nuclear export of DDX3 is mediated by the N-terminal conserved NES
Our data clearly demonstrates that the conserved N-terminal NES is
required for export of human DDX3 from the nucleus in HeLa (Fig. 1)
and also HEK293 cells (not shown). Recent publications by Frohlich
et al. (2016) and Heerma van Voss et al. (2017b) share this assessment.
In co-immunoprecipitation experiments that we carried out in the
presence of non-hydrolysable Ran-GTP, DDX3 binding to endogenous
CRM-1 was also dependent on the N-terminal NES, as would be ex-
pected for classical CRM-1 cargo. However, Yedavalli et al (2004) had
previously shown that DDX3 binds to CRM-1 through a C-terminal re-
gion (311–507) and in a Ran-GTP-independent manner. It is not fully
clear to us what causes the discrepancy between these two findings. We
did detect weaker non-discriminatory binding of all DDX3 mutants to
CRM-1 in the absence of Ran-GTP (see expanded blots for CRM-1 IP
shown in Supplementary Fig. 2). However, in the presence of Ran-GTP,
which mimics conditions present in the nucleus, CRM-1 exclusively
bound NES-containing DDX3 constructs (Fig. 2 and Supplementary
Fig. 2). We are not sure whether non-NES mediated binding of DDX3 to
CRM-1 in the absence of Ran-GTP has a physiological function or is
caused by an experimental artefact.
As a side note, we usually saw exclusion of DDX3 from nucleoli
when nuclear accumulation of DDX3 was achieved by truncating the
NES or treating cells with LMB (e.g. Figs. 1 and 6). This is different to
the observations made by van Voss et al. (Heerma van Voss et al.,
2017b), who observed increased DDX3 staining in the nucleoli com-
pared to the nucleoplasm in their recent study. It is unclear what causes
these different staining patterns as both studies were performed in HeLa
cells, but it raises the interesting question whether DDX3 distribution
between nucleoli and nucleoplasm could also fluctuate depending on
Fig. 5. DDX3 becomes more nuclear in early mitosis. A+B: Endogenous DDX3 was stained in HeLa cells together with DAPI and either phospho-histone 3 (Ser28)
(p-H3) to identify mitotic chromatin (A) or tubulin to visualize the mitotic spindle (B). In each slide, cells at the different stages of mitosis were identified based on
the shape of the cell and nucleus, chromatin condensation level, and the shape of the mitotic spindle (B). For C–E, HeLa cells were arrested at different stages of the
cell cycle before staining for endogenous DDX3. For C, cells were arrested at G0/G1 with serum starvation. For D, cells were arrested in early S-phase with a double
thymidine block, and for E, cells were arrested at G2/M with nocodazole treatment. Images are representatives of approximately 10–20 mitotic cells that were
identified in each experiment, and experiments were repeated three times. White arrows indicate cells in prophase/pro-metaphase with increased nuclear DDX3.
White arrowheads indicate accumulation of DDX3 staining around the mitotic chromosomes (A) and the co-localisation with the mitotic spindle (B). BF: brightfield
image.
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unidentified cellular conditions. That DDX3 can traffic into different
nuclear compartments is also suggested by the distinct staining pattern
we observed for the N-terminally truncated DDX3 mutants 139–662
and 139–408, which resembled nuclear speckles (Figs. 1D and 3 D)
(Spector and Lamond, 2011). Thus, it is possible that DDX3 is pulled
into nucleoli or nuclear speckles depending on cellular conditions, e.g.
cellular stress or an increased requirement for ribosome biogenesis
(Boulon et al., 2010).
4.2. Multiple nuclear localization signals exist within the DDX3 sequence
We were also keen to identify the nuclear localization signals (NLS)
in DDX3, as no information is available to date about the regulation of
DDX3’s nuclear import. However, NLSs are harder to identify than
NESs, and several NLS prediction software programmes failed to iden-
tify strong hits within the DDX3 sequence. The putative classical NLS
identified by PSORT II (Nakai and Horton, 1999) between aa 211–219
(‘NLS1’) appears to be non-functional, as its mutation did not prevent
import of DDX3, even of the 139–408 truncated protein (Supplemen-
tary Fig. 3). ‘NLS1’ is also still present in the 139–408-truncated ‘NLS2’
mutant, which did not accumulate in the nucleus (Fig. 3D). Thus it is
unable to mediate import in the absence of ‘N-NLS’ and ‘NLS2’. Nu-
cImport (Mehdi et al., 2011) identified ‘NLS2’, a putative NLS between
aa 259–264, which is located in an exposed loop according to the DDX3
crystal structure. Mutation of this sequence alone also did not prevent
import of full-length DDX3 or the 1–408 truncation. However, addi-
tional truncation of the N-terminal tail largely prevented import
(Fig. 3D). This suggests that ‘NLS2’ (259–264) is functional, but that an
additional import signal is present between amino acids 1 and 139 of
DDX3 (a putative ‘N-NLS’), which is likely responsible for export of the
‘NLS2’-mutated 1–408 fragment. We also observed independent nuclear
import of the second recA-like domain of DDX3 (aa 409–572), which
contains neither ‘NLS2’ nor ‘N-NLS’. None of the NLS prediction pro-
grammes returned any hits for this region of DDX3, so we were unable
to further narrow done the sequence(s) in DDX3 that are responsible for
import of the C-terminal recA-like domain. The lack of putative NLSs in
this region of DDX3 might also indicate that it can be imported in an
unconventional manner, e.g. via Transportin in a PY-NLS independent
manner, via the Calmodulin pathway or perhaps "piggy backing" into
the nucleus with another protein (Wagstaff and Jans, 2009). In any
case, there clearly is redundancy in the NLSs present in DDX3, with us
having identified at least three regions in DDX3 that can independently
mediate its nuclear import.
4.3. Regulation of DDX3’s subcellular localization
With DDX3 inhibitors being developed as potential anti-cancer and
anti-viral drugs (Bol et al., 2015; Heerma van Voss et al., 2017a;
Heerma van Voss et al., 2018; Maga et al., 2011; Radi et al., 2012), it is
important to understand in detail how DDX3 contributes to different
cellular functions, especially those related to cellular growth, pro-
liferation, and migration, and genome integrity (Sharma and
Jankowsky, 2014). For this study, we investigated the nuclear-cyto-
plasmic shuttling of DDX3. Given the distinct cytoplasmic and nuclear
functions of DDX3, it is tempting to speculate that an alteration in the
nuclear-cytoplasmic distribution of DDX3 could affect its participation
in various cellular processes with downstream consequences for cellular
phenotypes. Indeed, it has been suggested that an alteration in DDX3’s
subcellular localization could be associated with malignant transfor-
mation (Chao et al., 2006; Heerma van Voss et al., 2017b). However,
one of these studies suggested that DDX3 is nuclear in untransformed
(epidermal) cells and cytoplasmic in tumour cells (squamous cell car-
cinoma) (Chao et al., 2006), while a more recent study suggested that
increased nuclear DDX3 (which was defined as being present in more
than 1% of cells) correlates with worse patient outcome, larger tumour
size, positive lymph nodes, higher grade cancers and (although not
statistically significant) mitotic activity, in cohorts of colorectal and
breast cancer patients (Heerma van Voss et al., 2017b). When we
started this study, we had hoped to identify conditions that lead to
increased nuclear accumulation of DDX3. During SeV infection, DDX3
becomes phosphorylated on multiple serine residues by the kinases
Fig. 6. Mutation of putative Cyclin B phosphorylation sites in DDX3 does
not affect import or export of DDX3. Threonine 204 and 323, which have
been described as phosphorylation sites for Cyclin B, were mutated to either
alanine (TA2) or aspartic acid (TD2) to generate phospho-deficient and phos-
phor-mimetic mutants respectively. Expression vectors for the two Ha-tagged
DDX3 mutants (DDX3mt) were then transfected into HeLa cells, and localiza-
tion of the DDX3 mutants visualized by staining with an antibody for the Ha-
epitope tag, followed by an Alexa Fluor488-labelled secondary antibody. DAPI
DNA stain was used to visualize the nucleus. Where indicated, cells were treated
with 20 nM Leptomycin B (LMB) for 3 h. Images shown are representative of 2
repeat experiments with multiple frames collected in each experiment.
Fig. 7. DDX3 expression is upregulated
during G2/M phase. A: HeLa cells were either
left untreated or arrested at different cell cycle
stages with thymidine (S-Phase), nocodazole
(G2/M) or serum starvation (G0/1). Cell lysates
were prepared from equal number of cells and
subjected to SDS-PAGE and Western Blot
Analysis with the indicated antibodies. B: Cells
were first arrested in S-Phase with a double
thymidine block and then released into normal
growth medium. Samples for SDS-PAGE and
Western Blot analysis were collected every 3 h post release. Each subfigure is representative of two experiments.
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IKKε/TBK1 and it has been suggested to subsequently act as a tran-
scriptional regulator of the IFNβ promoter (Gu et al., 2013; Soulat et al.,
2008). The High Content analysis detected only a minor, but statisti-
cally significant increase in nuclear DDX3 1 h and 24 h after infection.
(Fig. 4A and B). Therefore, DDX3’s role in the IFN induction pathway is
either mainly cytoplasmic or nuclear retention of a small fraction of the
overall cellular pool of DDX3 is sufficient to mediate its transcriptional
regulation of the ifnb promoter. Unfortunately, due to the redundancy
of the NLSs in DDX3, we were unable to generate an import-deficient
point mutant of DDX3 that would have helped to clarify this question.
Similarly, DDX3 has also been suggested to act in the DNA damage
response (Sun et al., 2013), but exposure of cells to etoposide only in-
duced minor changes in the nuclear-cytoplasmic distribution of DDX3
according to our HC analysis (Fig. 4). Thus, DDX3’s nucleo-cytoplasmic
distribution seemed to be largely refractory to various different cellular
stimuli. In theory, what could cause nuclear accumulation of DDX3?
Certainly, defects in the CRM-1 pathway or loss of DDX3’s N-terminal
NES would result in clear nuclear retention of DDX3 based on our data
and also shown in Heerma van Voss et al. (2017b). Nuclear retention of
DDX3 could also be caused by enhanced binding of DDX3 to nuclear
proteins or chromatin, limiting its export via CRM-1 indirectly. While
we failed to show regulation of DDX3’s localization by phosphorylation
at T204 and T323, other post-translational modifications of DDX3 could
enhance its binding to nuclear factors, and thereby increase its nuclear
localization. Could increased import rather than decreased export drive
nuclear accumulation of DDX3? Theoretically this is certainly possible,
especially given the fact that the NLSs in DDX3 appear to be rather
weak. However, a recent study attempted to enhance nuclear import of
DDX3 by attaching additional SV40-derived consensus NLSs. Surpris-
ingly, this did not have a major effect on localization of DDX3, sug-
gesting that export is extremely efficient and that reduced export is the
key factor regulating nuclear accumulation of DDX3 in cases where this
does occur (Heerma van Voss et al., 2017b).
4.4. Alteration of DDX3’s subcellular localization and expression level
during mitosis
We observed an increased accumulation of DDX3 in the nucleus
during early mitosis, namely during prophase or prometaphase. This
was visible in unsynchronized Hela cells where we phenotypically
identified early mitotic cells, and further confirmed by staining of DDX3
in cells that were arrested in prometaphase by thymidine/nocodazole
treatment (Fig. 5). In addition, western blot analysis demonstrated in-
creased DDX3 protein levels during early mitosis. Presumably, this in-
crease in (nuclear) DDX3 is linked to its role in centrosome regulation
and chromosome segregation during mitosis, as described in two pre-
vious studies (Chen et al., 2017; Pek and Kai, 2011). Pek at al. sug-
gested that DDX3 localises close to condensing chromosomes during
prophase/prometaphase in HeLa cells (Pek and Kai, 2011), and the
recent study by Chen et al. demonstrated co-localisation of DDX3 with
centrosomes (Chen et al., 2017). Our images also suggest an association
of DDX3 with the mitotic spindle during metaphase through to cyto-
kinesis (Fig. 5B). Chen et al. also showed that knocking down DDX3
expression slows down progression of the cell cycle through G2/M
phase (Chen et al., 2017), suggesting that increased expression and
nuclear accumulation of DDX3 might be required for progressing cells
through G2/M.
The mechanism behind the increased nuclear accumulation of DDX3
during mitosis is unclear. We had hypothesized that phosphorylation of
DDX3 by Cyclin B, which is upregulated during early mitosis and has
been shown to phosphorylate DDX3 at Thr204 and Thr323 (Sekiguchi
et al., 2007), could mediate increased nuclear import or retention of
DDX3. However, mutation of these two threonine residues to phospho-
mimetic aspartic acid did not induce nuclear accumulation of DDX3
(Fig. 6), thus we were unable to find evidence for this hypothesis. It
would be interesting to address in future studies whether other post-
translation modifications of DDX3 that occur in a cell-cycle dependent
manner facilitate its nuclear retention.
Our observation that DDX3’s expression and nuclear localization is
increased during early mitosis should be relevant when interpreting
DDX3 staining in tumour samples. Is it possible that increased nuclear
DDX3 expression in tumour samples is due to the higher mitotic activity
of tumour cells compared to normal tissue cells? In this context, it will
be important to clarify in future studies whether increased nuclear
DDX3 is a ‘symptom’ of cells entering mitosis, or whether nuclear DDX3
is an active driver of mitotic activity. It would be useful to identify
effectors of DDX3’s nuclear accumulation and to elucidate its down-
stream consequences.
5. Conclusion
In this paper we clarified that the conserved N-terminal NES is re-
quired for nuclear export of human DDX3 and identified at least three
regions in DDX3 that contain independent NLSs. We also demonstrated
that nuclear localisation and protein expression levels of DDX3 are in-
creased during mitotic prophase, which could be linked to its proposed
role in chromosome segregation and has relevance for a potential use of
DDX3 expression as a biomarker in human cancers.
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